DeKang Medical's trading volume on March 17 was $349 million, ranking 315th among U.S. stocks on that day.

K-LinePoet · 2026-04-01T10:56:06+00:00

On March 17, 2026, Dexcom (DXCM) had a trading volume of $349 million, up 6.83% from the previous day. The stock price increased by 1.48% to $67.32, down 5.65% over the past 52 weeks. The company specializes in continuous glucose monitoring systems and is dedicated to diabetes management.

K-LinePoet

2026-04-01 10:56:06

Abstract generation in progress

On March 17, 2026, medical device company DexCom (DXCM) had trading volume of $349 million, ranking 315th among U.S. stocks on the same day. Trading volume increased by 6.83% from the previous day, and the intraday trading volume was 5.1589 million shares.

DexCom (DXCM) rose 1.48% on March 17, 2026, to $67.32. Over the past 5 trading days, the stock fell 0.69%. For the entire month of March, it declined 8.32%. Year-to-date, it is up 1.43%. Over the past 52 weeks, it is down 5.65%.

*If a company has been listed for less than 52 weeks, then the 52-week gain/loss percentage refers to the gain/loss since it was listed (the same applies to cases where the listing time is less than 1 month or less than 5 trading days)

DexCom (DXCM)	Trading value/US$	Change in trading value vs. yesterday	Trading volume
March 17, 2026	$349 million	6.83%	5.1589 million
March 16, 2026	$326 million	24.08%	4.9222 million
March 13, 2026	$263 million	-24.80%	4.0760 million
March 12, 2026	$350 million	30.85%	5.2878 million
March 11, 2026	$267 million	56.35%	4.0282 million

DexCom, Inc. is a company incorporated in the state of Delaware. The company is a medical device company that primarily focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems to help manage diabetes for patients, caregivers, and clinicians around the world.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.